STAT3 Relays a Differential Response to Melanoma-Associated <i>NRAS</i> Mutations
Melanoma patients carrying an oncogenic <i>NRAS</i> mutation represent 20% of all cases and present worse survival, relapse rate and therapy response than patients with wild type <i>NRAS</i> or with <i>BRAF</i> mutations. Nevertheless, no efficient targeted therap...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/1/119 |